Identifying high-risk patients with SMM & MGUS to prevent progression to active myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, talks on the importance of better understanding multiple myeloma precursor conditions like smoldering myeloma or monoclonal gammopathy of undetermined significance (MGUS) to identify patients at high risk of progression to active myeloma and to develop strategies to prevent disease progression. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.